MK-7655

Known as: relebactam 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2017
0246820112017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Resistance to antibiotics among bacterial pathogens is rapidly spreading, and therapeutic options against multidrug-resistant… (More)
Is this relevant?
2017
2017
Objectives The β-lactamase inhibitor relebactam can restore imipenem activity against imipenem non-susceptible pathogens… (More)
Is this relevant?
2017
2017
The β-lactamase inhibitor relebactam inactivates class A β-lactamases, including KPC-type carbapenemases, and class C… (More)
Is this relevant?
2015
2015
Imipenem with relebactam was active against Escherichia coli, Klebsiella pneumoniae, and Enterobacter spp., including K… (More)
Is this relevant?
2015
2015
Nach Jahren der Stagnation sind inzwischen wieder zahlreiche Neuentwicklungen im Bereich der antibakteriellen Substanzen zu… (More)
Is this relevant?
2014
2014
β-Lactamase inhibitors with a bicyclic urea core and a variety of heterocyclic side chains were prepared and evaluated as… (More)
Is this relevant?
2013
2013
OBJECTIVES MK-7655 is a novel inhibitor of class A and C β-lactamases. We investigated its potential to protect imipenem… (More)
Is this relevant?
2012
2012
Carbapenem-resistant bacteria represent a significant treatment challenge due to the lack of active antimicrobials available. MK… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
2012
2012
The scarcity of new antibiotics against drug-resistant bacteria has led to the development of inhibitors targeting specific… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
2011
2011
MK-7655 (1) is a β-lactamase inhibitor in clinical trials as a combination therapy for the treatment of bacterial infection… (More)
Is this relevant?